Predictive Oncology Inc. (POAI): Price and Financial Metrics

Predictive Oncology Inc. (POAI): $2.74

0.04 (-1.44%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add POAI to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#233 of 350

in industry

POAI Price/Volume Stats

Current price $2.74 52-week high $13.88
Prev. close $2.78 52-week low $2.47
Day low $2.65 Volume 9,675
Day high $2.78 Avg. volume 20,999
50-day MA $2.98 Dividend yield N/A
200-day MA $3.66 Market Cap 11.13M

POAI Stock Price Chart Interactive Chart >

POAI POWR Grades

  • POAI scores best on the Growth dimension, with a Growth rank ahead of 91.03% of US stocks.
  • The strongest trend for POAI is in Growth, which has been heading up over the past 123 days.
  • POAI's current lowest rank is in the Momentum metric (where it is better than 7.32% of US stocks).

POAI Stock Summary

  • POAI has a market capitalization of $13,733,214 -- more than approximately just 6.75% of US stocks.
  • With a year-over-year growth in debt of 1,302.64%, PREDICTIVE ONCOLOGY INC's debt growth rate surpasses 99.16% of about US stocks.
  • The volatility of PREDICTIVE ONCOLOGY INC's share price is greater than that of 88.23% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to PREDICTIVE ONCOLOGY INC are PEGY, ISDR, SMTI, UBFO, and MBIN.
  • POAI's SEC filings can be seen here. And to visit PREDICTIVE ONCOLOGY INC's official web site, go to www.predictive-oncology.com.

POAI Valuation Summary

  • In comparison to the median Healthcare stock, POAI's price/earnings ratio is 102.4% lower, now standing at -0.7.
  • Over the past 166 months, POAI's EV/EBIT ratio has gone up 1.3.

Below are key valuation metrics over time for POAI.

Stock Date P/S P/B P/E EV/EBIT
POAI 2023-12-29 7.4 1.2 -0.7 -0.2
POAI 2023-12-28 7.6 1.2 -0.7 -0.3
POAI 2023-12-27 7.4 1.2 -0.7 -0.2
POAI 2023-12-26 7.4 1.2 -0.7 -0.2
POAI 2023-12-22 7.1 1.1 -0.7 -0.2
POAI 2023-12-21 6.6 1.0 -0.7 -0.2

POAI Growth Metrics

    Its 3 year net income to common stockholders growth rate is now at -64.71%.
  • The 4 year revenue growth rate now stands at 171.39%.
  • Its 5 year net income to common stockholders growth rate is now at -267.51%.
POAI's revenue has moved up $298,057 over the prior 49 months.

The table below shows POAI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1.618479 -12.87992 -25.57803
2022-06-30 1.476315 -13.10976 -26.95657
2022-03-31 1.454931 -11.98053 -19.13918
2021-12-31 1.42068 -12.20893 -19.65717
2021-09-30 1.237975 -10.76877 -23.37064
2021-06-30 1.405069 -11.06363 -24.79463

POAI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • POAI has a Quality Grade of D, ranking ahead of 8.37% of graded US stocks.
  • POAI's asset turnover comes in at 0.042 -- ranking 162nd of 186 Medical Equipment stocks.
  • INO, EYES, and PETV are the stocks whose asset turnover ratios are most correlated with POAI.

The table below shows POAI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.042 0.637 -7.254
2021-03-31 0.047 0.635 -18.054
2020-12-31 0.055 0.643 58.433
2020-09-30 0.052 0.629 16.113
2020-06-30 0.050 0.616 9.041
2020-03-31 0.052 0.621 9.870

POAI Price Target

For more insight on analysts targets of POAI, see our POAI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.50 Average Broker Recommendation 1.5 (Moderate Buy)

Predictive Oncology Inc. (POAI) Company Bio


Predictive Oncology Inc. operates as a biotechnology company. The Company focuses focuses on applying data and artificial intelligence to personalized medicine and drug discovery. Predictive Oncology serves customers worldwide.


POAI Latest News Stream


Event/Time News Detail
Loading, please wait...

POAI Latest Social Stream


Loading social stream, please wait...

View Full POAI Social Stream

Latest POAI News From Around the Web

Below are the latest news stories about PREDICTIVE ONCOLOGY INC that investors may wish to consider to help them evaluate POAI as an investment opportunity.

Predictive Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update

Company to host investor call and webcast today, November 14th, at 8:30am EDTPITTSBURGH, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the three and nine months ended Sep

Yahoo | November 14, 2023

Predictive Oncology Completes AI-driven Study of Ovarian Cancer with UPMC Magee-Womens Hospital

PITTSBURGH, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announced today that it has completed a multi-year study with UPMC Magee-Womens Hospital. The objective of the study was to evaluate the use of AI to build multi-omic machine learning (ML) models and test if these models can learn associations between the datasets and ovarian cancer patient short- and long-term survival. “This study incorporated one of the la

Yahoo | November 8, 2023

Predictive Oncology to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on Tuesday, November 14, 2023

Management to host conference call and webcast at 8:30am EDTEAGAN, Minn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that

Yahoo | November 7, 2023

3 AI Stocks Worth Buying Now for Multibagger Returns

With no signs of artificial intelligence cooling, we could be looking at a potential $1.8 trillion opportunity for AI stocks.

Ian Cooper on InvestorPlace | October 10, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're starting the final day of trading this week with a dive into the biggest pre-market stock movers worth watching for Friday!

William White on InvestorPlace | August 18, 2023

Read More 'POAI' Stories Here

POAI Price Returns

1-mo -15.95%
3-mo -16.72%
6-mo -14.38%
1-year -51.69%
3-year -87.55%
5-year -98.17%
YTD -16.72%
2023 -46.35%
2022 -67.79%
2021 29.97%
2020 -71.94%
2019 -57.90%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!